|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:accessories
|
healthcare providers
|
|
gptkbp:acquisition
|
gptkb:Daiichi_Sankyo_Europe_Gmb_H
gptkb:Ranbaxy_Laboratories
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:anti-influenza_drug
|
Daiichi Sankyo's anti-influenza drug business
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:awards
|
industry recognition
sustainability awards
innovation awards
|
|
gptkbp:ceo
|
gptkb:Seigo_Kikuchi
J. M. H. (J) Kato
|
|
gptkbp:clinical_trial
|
ongoing
efficacy studies
collaborative
safety studies
safety profile
Phase III studies
Phase I studies
Phase II studies
anti-influenza drugs
antiviral efficacy
|
|
gptkbp:collaboration
|
government health agencies
|
|
gptkbp:collaborations
|
government agencies
academic institutions
research organizations
biopharmaceutical companies
|
|
gptkbp:community_health
|
influenza outbreaks
|
|
gptkbp:community_outreach
|
health education
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._Masato_Saito
|
|
gptkbp:drug_safety
|
monitoring programs
|
|
gptkbp:employees
|
approximately 15,000
|
|
gptkbp:focus
|
research and development
|
|
gptkbp:founded
|
gptkb:2005
1899
|
|
gptkbp:founder
|
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:global_presence
|
over 20 countries
|
|
gptkbp:goal
|
develop effective antiviral treatments
|
|
gptkbp:grants
|
influenza studies
|
|
gptkbp:has_advisory_board
|
medical experts
|
|
gptkbp:has_research_center
|
gptkb:Princeton,_New_Jersey
gptkb:Tokyo
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
gptkbp:healthcare
|
affordable medications
oral and injectable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo
|
|
gptkbp:innovation
|
drug development
|
|
gptkbp:instruction_set
|
biologics
small molecules
innovative therapies
antiviral agents
|
|
gptkbp:invention
|
numerous
anti-influenza drugs
|
|
gptkbp:investment
|
gptkb:biotechnology
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
global
|
|
gptkbp:market_share
|
anti-influenza drugs
|
|
gptkbp:marketing_strategy
|
gptkb:healthcare_professionals
patients
|
|
gptkbp:number_of_employees
|
over 15,000
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Eisai
gptkb:Novartis
research institutions
|
|
gptkbp:partnerships
|
academic institutions
community health programs
|
|
gptkbp:patient_education
|
influenza prevention
|
|
gptkbp:philanthropy
|
disaster relief efforts
education programs
healthcare initiatives
|
|
gptkbp:product
|
gptkb:Oseltamivir
gptkb:Peramivir
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
|
|
gptkbp:provides_guidance_on
|
influenza treatment
|
|
gptkbp:publications
|
research findings
|
|
gptkbp:regulatory_compliance
|
pharmaceutical regulations
|
|
gptkbp:research
|
gptkb:virus
|
|
gptkbp:research_areas
|
gptkb:diabetes
neurology
infectious diseases
pain management
respiratory diseases
gastroenterology
|
|
gptkbp:research_focus
|
oncology
cardiovascular diseases
infectious diseases
immunology
|
|
gptkbp:research_interest
|
billions of yen
|
|
gptkbp:revenue
|
$10 billion (2020)
pharmaceutical sales
|
|
gptkbp:social_responsibility
|
health initiatives
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:strategy
|
global expansion
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:supply_chain
|
global distribution
|
|
gptkbp:sustainability
|
environmental practices
|
|
gptkbp:sustainability_initiatives
|
gptkb:healthcare_access
community engagement
environmental responsibility
|
|
gptkbp:treatment
|
treatment effectiveness
|
|
gptkbp:website
|
www.daiichisankyo.com
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca
gptkb:2002_FIFA_World_Cup
gptkb:rifampicin
|
|
gptkbp:bfsLayer
|
4
|